HS-20093 combination safety study for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of cancer that has spread or cannot be removed with surgery, and standard treatments have not worked or are not available.
- You must have at least one tumor that can be measured with a scan (like a CT scan), and it must be outside your brain.
- You must be willing to provide a sample of your tumor (either a fresh biopsy or a stored one from a previous procedure).
- You must be in good enough health to do daily activities (ECOG performance status 0 or 1), and your doctor expects you to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This phase 1 study tests an investigational drug called HS-20108 in people with advanced solid tumors. It aims to find a safe dose and see how well the drug works against cancer.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
This trial tests a new drug called HS-20105 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.